FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
THOUSAND OAKS, Calif., Dec. 6, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq) for all approved indications of the reference product, Remicade®... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 6, 2019 Category: Drugs & Pharmacology Source Type: news
Reimbursing infliximab for Crohn's disease cost effective in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 30, 2019 Category: Drugs & Pharmacology Source Type: news
J & J blockbuster loses ground to biosimilars despite Quebec court ruling
Johnson& Johnson's Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec's public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
J & J's Remicade losing ground in Quebec health plan despite court victory
Johnson& Johnson's Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec's public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Therapeutic IBD Drug Concentrations May Vary With Different Assays Therapeutic IBD Drug Concentrations May Vary With Different Assays
In patients with inflammatory bowel disease (IBD), concentrations of infliximab and adalimumab varied depending on whether they were assessed with the Enzyme-Linked Immunosorbent Assay (ELISA) or the Homogeneous Mobility Shift Assay (HMSA), researchers found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Infliximab Induction in Refractory Acute Severe Colitis Infliximab Induction in Refractory Acute Severe Colitis
Does an accelerated induction rescue therapy regimen of infliximab improve response rates compared to standard-dose therapy in patients with steroid-refractory acute severe colitis?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 21, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Effectiveness of Infliximab vs. Biosimilar CT-P13 in Colitis Effectiveness of Infliximab vs. Biosimilar CT-P13 in Colitis
The infliximab biosimilar CT-P13 has been approved for the treatment of ulcerative colitis. Are they clinically equivalent in safety and efficacy?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 25, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
infliximab (Remicade)
Title: infliximab (Remicade)Category: MedicationsCreated: 12/13/1999 12:00:00 AMLast Editorial Review: 9/20/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 20, 2019 Category: Drugs & Pharmacology Source Type: news
Effects of Infliximab Withdrawal and Reintroduction in Ankylosing Spondylitis Patients in Persistent Clinical Remission
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 15, 2019 Category: Orthopaedics Tags: CME Article Source Type: news
FTC probing J & amp;J over arthritis drug Remicade
The organization issued a civil investigative demand to the drugmaker to see if its biosimilar defense strategy violates federal antitrust laws. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 30, 2019 Category: Pharmaceuticals Source Type: news
J & J says FTC probing efforts to protect arthritis drug Remicade
The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday. (Source: Reuters: Health)
Source: Reuters: Health - July 30, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
Withdrawal of Infliximab Therapy in Ankylosing Spondylitis Withdrawal of Infliximab Therapy in Ankylosing Spondylitis
Should infliximab withdrawal be considered for ankylosing spondylitis patients who have achieved clinical remission? What are the effects of reintroduction?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Biologics in IBD: More Thoughtful Use Could Improve Outcomes Biologics in IBD: More Thoughtful Use Could Improve Outcomes
The marketplace introduction of infliximab for the treatment of IBD did not reduce hospitalization or surgery rates in a large population of patients with Crohn disease and ulcerative colitis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Infliximab Introduction Has Not Cut IBD-Related Hospitalizations
FRIDAY, June 14, 2019 -- Marketplace introduction of infliximab has not resulted in reductions in the population rates of inflammatory bowel disease (IBD)-related hospitalizations or intestinal resections or colectomies, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2019 Category: Pharmaceuticals Source Type: news
Targeting Inflammation May Help Bipolar Depression Subtype Targeting Inflammation May Help Bipolar Depression Subtype
The anti-inflammatory agent infliximab may improve depressive symptoms in patients with bipolar depression and a history of childhood trauma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 20, 2019 Category: Consumer Health News Tags: Psychiatry News Source Type: news
